Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$9.36 USD
+0.67 (7.71%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $9.25 -0.11 (-1.18%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Acrivon Therapeutics, Inc. (ACRV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$22.00 | $30.00 | $17.00 | 153.16% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Acrivon Therapeutics, Inc. comes to $22.00. The forecasts range from a low of $17.00 to a high of $30.00. The average price target represents an increase of 153.16% from the last closing price of $8.69.
Analyst Price Targets (7 )
Broker Rating
Acrivon Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.22 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.22 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, eight are Strong Buy, representing 88.89% of all recommendations. A month ago, Strong Buy represented 88.89%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.22 | 1.22 | 1.22 | 1.22 | 1.22 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
8/13/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/13/2024 | H.C. Wainwright & Co. | Emily Bodnar | Strong Buy | Strong Buy |
5/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/29/2024 | LadenburgThalmann | Aydin Huseynov | Strong Buy | Hold |
4/25/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
4/1/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
3/1/2024 | JMP Securities | Silvan C Tuerkcan | Not Available | Strong Buy |
10/5/2023 | Maxim Group | Michael Okunewitch | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.22 |
ABR (Last week) | 1.22 |
# of Recs in ABR | 9 |
Average Target Price | $22.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 253 |
Current Quarter EPS Est: | -0.56 |